Skip to main content

MECANISMOS QUE INVOLUCRAN A LOS RECEPTORES NR4A Y A LOX EN LA CALCIFICACION CARDIOVASCULAR: ESTABLECIENDO LAS BASES PARA NUEVAS ESTRATEGICAS TERAPEUTICAS

RTI2018-094727-B-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2018
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Nr4a3: A key nuclear receptor in vascular biology, cardiovascular remodeling and beyond

  • Martínez-González, José
  • Cañes, Laia
  • Alonso, Judith
  • Ballester-Servera, Carme
  • Rodríguez-Sinovas, Antonio
  • Corrales, Irene
  • Rodríguez-Sinovas, Cristina
The mechanisms committed in the activation and response of vascular and inflammatory immune cells play a major role in tissue remodeling in cardiovascular diseases (CVDs) such as atherosclerosis, pulmonary arterial hypertension, and abdominal aortic aneurysm. Cardiovascular remodeling entails interrelated cellular processes (proliferation, survival/apoptosis, inflammation, extracellular matrix (ECM) synthesis/degradation, redox homeostasis, etc.) coordinately regulated by a reduced number of transcription factors. Nuclear receptors of the subfamily 4 group A (NR4A) have recently emerged as key master genes in multiple cellular processes and vital functions of different organs, and have been involved in a variety of high‐incidence human pathologies including atherosclerosis and other CVDs. This paper reviews the major findings involving NR4A3 (Neuron‐derived Orphan Receptor 1, NOR‐1) in the cardiovascular remodeling operating in these diseases., This research was funded by the Spanish Ministerio de Ciencia e Innovación (RTI2018- 094727-B-100), Instituto de Salud Carlos III (ISCIII; PI18/0919 and PI20/01649), the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR; 2017-SGR-00333). The study was cofounded by Fondo Europeo de Desarrollo Regional (FEDER), a way to make Europe. C.B.-S. is supported by a FPU fellowship (Ministerio de Ciencia, Innovación y Universidades).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

NOD1 in the interplay between microbiota and gastrointestinal immune adaptations

  • Fernández-García, Victoria
  • González-Ramos, Silvia
  • Martín-Sanz, Paloma
  • García del Portillo, Francisco
  • Moisés Laparra, José
  • Boscá, Lisardo
© 2021 The Author(s)., Nucleotide-binding oligomerization domain 1 (NOD1), a pattern recognition receptor (PRR) that detects bacterial peptidoglycan fragments and other danger signals, has been linked to inflammatory pathologies. NOD1, which is expressed by immune and non-immune cells, is activated after recognizing microbe-associated molecular patterns (MAMPs). This recognition triggers host defense responses and both immune memory and tolerance can also be achieved during these processes. Since the gut microbiota is currently considered a master regulator of human physiology central in health and disease and the intestine metabolizes a wide range of nutrients, drugs and hormones, it is a fact that dysbiosis can alter tissues and organs homeostasis. These systemic alterations occur in response to gastrointestinal immune adaptations that are not yet fully understood. Even if previous evidence confirms the connection between the microbiota, the immune system and metabolic disorders, much remains to be discovered about the contribution of NOD1 to low-grade inflammatory pathologies such as obesity, diabetes and cardiovascular diseases. This review compiles the most recent findings in this area, while providing a dynamic and practical framework with future approaches for research and clinical applications on targeting NOD1. This knowledge can help to rate the consequences of the disease and to stratify the patients for therapeutic interventions., The review was written by authors that work in a laboratory where projects are supported by: Ministerio de Economía, Industria y Competitividad/Agencia Estatal de Investigación 10.13039/501100011033 (RTI2018-094727-B100, SAF2017-82436-R, BIO2016-77639-P, PID2019-108977-RBI00 and PID2020-113238-RBI00), Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CB16/11/00222), Consorcio de Investigación en Red de la Comunidad de Madrid, S2017/BMD-3686 and Fondo Europeo de Desarrollo Regional.